Eiropas Savienība - angļu - EMA (European Medicines Agency)

warner chilcott uk ltd. - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - intrinsa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

warner chilcott  deutschland gmbh - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - livensa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

alvogen inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 60 mg - fluoxetine tablets are indicated for the treatment of: the use of maois intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine is contraindicated because of an increased risk of serotonin syndrome. the use of fluoxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.6) and warnings and precautions (5.2)] . starting fluoxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration ( 2.7 ) and warnings and precautions (5.2 )] . the use of fluoxetine is contraindicated with the following: pimozide and thioridazine prolong the qt interval. fluoxetine can increase the levels of pimozide and thioridazine through inhibition of cyp2d6. fluoxetine can also prolong the qt interval. pregnancy category c —fluoxetine should be used duri

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

almatica pharma inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 60 mg - fluoxetine tablets are indicated for the treatment of: the use of maois intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine is contraindicated because of an increased risk of serotonin syndrome. the use of fluoxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.6) and warnings and precautions (5.2)] . starting fluoxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration ( 2.7) and warnings and precautions (5.2)] . the use of fluoxetine is contraindicated with the following: pimozide and thioridazine prolong the qt interval. fluoxetine can increase the levels of pimozide and thioridazine through inhibition of cyp2d6. fluoxetine can also prolong the qt interval. pregnancy exposure registry there is a pregnancy exposure

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - risedronate sodium anhydrous (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risedronate sodium delayed-release tablets are contraindicated in patients with the following conditions: -   abnormalities of the esophagus which delay esophageal empt

Nigērija - angļu - NAFDAC (National Agency for Food and Drugs Administration and Control)

carbamazepine 200mg

Nigērija - angļu - NAFDAC (National Agency for Food and Drugs Administration and Control)

phenoxymethyl penicillin potassium 250mg

Kenija - angļu - Pharmacy and Poisons Board

comet healthcare limited homabay road off enterprise road industrial area, - dextromethorphan hydrobromide bp, phenylephrine… - suspension and effervescent granules for oral - 10:5:5:1.5/5ml - expectorants excluding combinations with cough

Kenija - angļu - Pharmacy and Poisons Board

philmed limited homabay road off enterprise road industrial area, - salbutamol sulphate bp equivalent to salbutamol,… - syrup - 1mg, 2mg, 50mg, 0.5mg - adrenergics inhalants: adrenergics and other

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

iphilo - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - purpose:sanitizer uses: disinfection of hands and skin